Conversely, in MMR-competent (cMMR) patients, BRAF mutations convey a poor prognosis and their prognosis declines further in BRAF mutant metastatic disease.4 Furthermore, dMMR/BRAF mutant patients have a 5-year survival rate of 65% compared to 46% for cMMR/BRAF mutant patients. The gene discussed is BRAF; the disease is metastatic neoplasm.